Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine

Launched by CENTRE GEORGES FRANCOIS LECLERC · Oct 29, 2020

Keywords

ClinConnect Summary

The EXOMA2 study is a clinical trial that is looking at two different ways of analyzing genetic information from cancer patients to find the best treatment options. The "simple" analysis checks for specific mutations, while the "complex" analysis provides more detailed information about the cancer's DNA, including types of mutations and other genetic characteristics that could influence treatment decisions. The goal of this study is to see if the additional information from the complex analysis can help doctors choose therapies that wouldn't be identified using the simpler method.

To participate in this trial, you need to be at least 18 years old, weigh more than 30 kg, and have a specific type of advanced cancer that is being treated for the first time. You'll also need to have enough tumor tissue and blood samples available for testing. If you join the study, you will undergo genetic analysis to help guide your treatment. It's important to know that this study is currently recruiting participants, and your involvement will help researchers understand the potential benefits of more detailed genetic testing in cancer care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years old
• • 2. Weight\> 30 Kg
• • 3. Histological or cytological evidence of the diagnosis of a metastatic or locally advanced solid tumor
• • 4. Patient in 1st line of treatment for metastatic or locally advanced disease
• • 5. Tumor material available in sufficient and usable quantity for the analyzes required by the study
• • 6. Request for exome analysis to be carried out when initiating the 1st or 2nd line of treatment (line initiated at the time of inclusion)
• • 7. Life expectancy estimated to be probably ≥ 6 months.
• • 8. WHO ≤ 1
• • 9. Patient capable and willing to follow all study procedures in accordance with the protocol
• • 10. Patient having understood the purpose, risks and constraints of the study and having signed and dated the consent form
• • 11. Patient affiliated to the social security scheme.
• Exclusion Criteria:
• • 1. Tumor material not available or biopsy not possible.
• • 2. Inability to take a blood test.
• • 3. Refusal of genetic analysis.
• • 4. Patient likely to progress within 3 months of inclusion in the study.
• • 5. History of HIV / HBV / HCV infection.
• • 6. Patient already included in the EXOMA or EXOMA2 study.
• • 7. Woman who is pregnant, may be, or is breastfeeding.
• • 8. Persons deprived of their liberty or under guardianship (including curatorship).